CRSP CRISPR Therapeutics (CRSP) Reports Wider Q4 Loss of $1.37/Share on Zero Revenue; Shares Plunge 10% 5 hours ago CRISPR Therapeutics posts wider-than-expected Q4 loss of $1.37/share on zero revenue; shares sink 10% as cash burn accelerates.